Suppr超能文献

用Etest法测定替加环素最低抑菌浓度的验证与重复性评估

Validation and reproducibility assessment of tigecycline MIC determinations by Etest.

作者信息

Bolmström Anne, Karlsson Asa, Engelhardt Anette, Ho Phion, Petersen Peter J, Bradford Patricia A, Jones C Hal

机构信息

AB BIODISK, Solna, Sweden.

出版信息

J Clin Microbiol. 2007 Aug;45(8):2474-9. doi: 10.1128/JCM.00089-07. Epub 2007 May 23.

Abstract

A multicenter study was conducted to validate Etest tigecycline compared to the Clinical Laboratory Standards Institute reference broth microdilution and agar dilution methodologies. A large collection of gram-negative (n = 266) and gram-positive (n = 162) aerobic bacteria, a collection of anaerobes (n = 385), and selected collections of nonpneumococcal streptococci (n = 369), Streptococcus pneumoniae (n = 372), and Haemophilus influenzae (n = 372) were tested. Strains with reduced susceptibility to tigecycline were used with all test methods. The Etest showed excellent inter- and intralaboratory reproducibility for all organism groups tested regardless of the test methodology. The essential agreement values with the reference method (+/-1 dilution) were >99% for the collection of gram-negative and gram-positive aerobes; >98% for the S. pneumoniae, H. influenzae, and anaerobe collections; and 100% for the group of nonpneumococcal streptococci. These results validate the performance accuracy and utility of Etest tigecycline and verify the reproducibility of this convenient predefined gradient methodology for tigecycline susceptibility determination.

摘要

开展了一项多中心研究,以验证Etest替加环素与临床实验室标准协会参考肉汤微量稀释法和琼脂稀释法相比的效果。对大量革兰氏阴性需氧菌(n = 266)、革兰氏阳性需氧菌(n = 162)、厌氧菌(n = 385)以及非肺炎链球菌(n = 369)、肺炎链球菌(n = 372)和流感嗜血杆菌(n = 372)的选定菌株进行了检测。所有检测方法均使用了对替加环素敏感性降低的菌株。无论采用何种检测方法,Etest对所有受试生物体组均显示出出色的实验室间和实验室内重复性。革兰氏阴性和革兰氏阳性需氧菌集合与参考方法(±1个稀释度)的基本一致率>99%;肺炎链球菌、流感嗜血杆菌和厌氧菌集合的基本一致率>98%;非肺炎链球菌组的基本一致率为100%。这些结果验证了Etest替加环素的性能准确性和实用性,并证实了这种方便的预定义梯度方法用于替加环素敏感性测定的可重复性。

相似文献

1
Validation and reproducibility assessment of tigecycline MIC determinations by Etest.
J Clin Microbiol. 2007 Aug;45(8):2474-9. doi: 10.1128/JCM.00089-07. Epub 2007 May 23.
2
Determination of disc breakpoints and evaluation of Etests for tigecycline susceptibility testing by the BSAC method.
J Antimicrob Chemother. 2007 Oct;60(4):770-4. doi: 10.1093/jac/dkm297. Epub 2007 Aug 18.
3
Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents.
Diagn Microbiol Infect Dis. 2005 Jul;52(3):181-6. doi: 10.1016/j.diagmicrobio.2005.05.005.
4
Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery.
Diagn Microbiol Infect Dis. 2010 Mar;66(3):308-13. doi: 10.1016/j.diagmicrobio.2009.10.018.
6
Tigecycline in vitro activity against gram-negative and gram-positive pathogens collected in Italy.
Chemotherapy. 2008;54(1):43-9. doi: 10.1159/000112415. Epub 2007 Dec 10.
7
Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of Gram-positive cocci.
Int J Antimicrob Agents. 2008 Nov;32 Suppl 3:S184-7. doi: 10.1016/S0924-8579(08)70025-6.
8
Epidemiological MIC cut-off values for tigecycline calculated from Etest MIC values using normalized resistance interpretation.
J Antimicrob Chemother. 2006 Mar;57(3):498-505. doi: 10.1093/jac/dki489. Epub 2006 Jan 12.
10
Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
Diagn Microbiol Infect Dis. 2006 Dec;56(4):437-44. doi: 10.1016/j.diagmicrobio.2006.07.005. Epub 2006 Sep 1.

引用本文的文献

2
Antimicrobial Susceptibility Testing for Enterococci.
J Clin Microbiol. 2022 Sep 21;60(9):e0084321. doi: 10.1128/jcm.00843-21. Epub 2022 Jun 13.
3
Phages for Phage Therapy: Isolation, Characterization, and Host Range Breadth.
Pharmaceuticals (Basel). 2019 Mar 11;12(1):35. doi: 10.3390/ph12010035.
4
Comparison of Etest, disk diffusion, and broth macrodilution for in vitro susceptibility testing of Rhodococcus equi.
J Clin Microbiol. 2015 Jan;53(1):314-8. doi: 10.1128/JCM.02673-14. Epub 2014 Nov 5.
7
In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli.
Antimicrob Agents Chemother. 2012 Aug;56(8):4516-8. doi: 10.1128/AAC.00234-12. Epub 2012 May 29.
10
In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital.
Eur J Clin Microbiol Infect Dis. 2009 Apr;28(4):381-4. doi: 10.1007/s10096-008-0629-9. Epub 2008 Sep 19.

本文引用的文献

2
Tigecycline: a review of preclinical and clinical studies of the first-in-class glycylcycline antibiotic.
Drugs Today (Barc). 2005 Oct;41(10):637-59. doi: 10.1358/dot.2005.41.10.937460.
9
Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).
Antimicrob Agents Chemother. 2004 Jun;48(6):2179-84. doi: 10.1128/AAC.48.6.2179-2184.2004.
10
Tetracycline therapy: update.
Clin Infect Dis. 2003 Feb 15;36(4):462-7. doi: 10.1086/367622. Epub 2003 Jan 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验